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Acute, severe and anaphylactoid reactions are very rare
with low-molecular-weight iron dextran, CosmoFer
R 
Sir,
It was with interest and surprise that I read the article by
Liliana Schaefer and Roland M Schaefer [1].
In this article, Liliana and Roland Schaefer do not dis-
tinguish between the adverse drug event profile of the old
high-molecular-weight iron dextrans that have been with-
drawn from the market of Europe ∼20 years ago and the
low-molecular-weight iron dextran marketed in 1992 as
INFeD
R  in the US and in 2001 as CosmoFer
R  in Europe
and overseas. The product is produced by Pharmacosmos
in Denmark and marketed in more than 40 countries.
Numerous articles, [2–7], including the Chertow arti-
cle [5] referenced by the Schaefers, document that the
high-molecular-weight iron dextran has many times more
adverse drug events than the low-molecular-weight iron
dextran. The high-molecular-weight iron dextran is today
marketed practically only in the USA under the brand Dex-
ferrum where the active pharmaceutical ingredient is pro-
duced by Vifor International. Vifor also produces iron su-
crose Venofer
R .
Low-molecular-weight iron dextrans have now been ad-
ministered in more than 70 million doses of 100 mg. The
CosmoFer
R  SmPCinEuropewasupdatedinJune2007and
concludes that anaphylactoid reactions are less than one in
ten thousand; this is the same as in the SmPC for Venofer
R 
iron sucrose.
IwouldexpectthatthenextrevisionoftheEuropeanBest
Practice Guidelines reflects the updated knowledge about
low-molecular-weight iron dextran, CosmoFer
R .
Conflict of interest statements. During 1999–2005 President of Nebo A/S
launched CosmoFer
R  worldwide. Nebo A/S has been merged into the
mother company Pharmacosmos A/S where I have the same responsibility
forCosmoFer
R  asExecutiveVice-PresidentofthePharmacosmosGroup.
I am a co-author of the referenced Chertow articles published in Nephrol
Dial Transplant [4,5].
Pharmacosmos A/S, Holbaek
Denmark
E-mail: ovn@pharmacosmos.com
Odd Vaage-Nilsen
1. Schaefer L, Schaefer RM. A primer on iron therapy. Nephrol Dial
Transplant 2007; 22: 2429–2431
2. McCarthy JT, Regnier CE, Loebertmann CL et al. Adverse events in
chronic hemodialysis patients receiving intravenous iron dextran—a
comparison of two products. Am J Nephrol 2000; 20: 455–462
3. Fletes R, Lazarus M, Gage J et al. Suspected iron dextran—related
adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;
37: 743–749
4. Chertow GM, Mason PD, Vaage-Nilsen O et al. On the relative safety
of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:
1571–1575
5. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse
drug events associated with parenteral iron. Nephrol Dial Transplant
2006; 21: 378–382
6. Case G. Maintaining Iron Balance with total-dose infusion of intra-
venous iron dextran. ANNA J 1998; 25: 65–68
7. CoyneDW,AdkinsonNF,NissensonARetal.Sodiumferricgluconate
complex in hemodialysis patients: II adverse reactions in iron dextran-
sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217–224
doi: 10.1093/ndt/gfn251
Advance Access publication 29 May 2008
Reply
Sir,
We appreciate the interest of O. Vaage-Nilsen who claims
that in our article [1] we had not distinguished between
high-molecular-weight (Dexferrum
R 
) and low-molecular-
weight (INFed
R 
) dextran. This of course is not the case.
We were quoting an article by Chertow et al. [2], of which
Mr Vaage-Nilsen is an author as well, clearly showing
that the reported numbers of life-threatening events over a
3-year period were 6/10.000.000 with iron sucrose versus
33/10.000.000 for the INFed iron dextran. Rare events in-
deed, but still a striking difference nonetheless. For these
reasons the European Best Practice Guidelines—published
in this learned journal do discourage the use of all iron
dextran species, irrespective of their molecular weight [3].
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